You are here

Home » Content

ALÜMINYUM TOKSISITESININ KALITE KONTROL AÇıSıNDAN DEĞERLENDIRILMESI

EVALUATION OF ALUMINIUM TOXICITY FROM THE POINT OF VIEW OF QUALITY CONTROL

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In this review, the relation of aluminium toxicity with human health is evaluated from the point of view of quality control. The main sources for aluminium entering the human body are cited and the aluminium limits for the water used in dialysis and parenteral solutions, raw materials and concentrated dialysis solutions and processes used for elimination the contaminants in water are given. The research on the absorption of aluminium gels and antiacids used orally for phosphate binding and peptic ulcer and the factors affecting absorption are reviewed. In these studies, the relation of the toxicity of this element with human health is emphazised. The serum and bone aluminium limits and results of the dialysis patients taking also oral preparations containing aluminium are given. At the end of the article proposals are given and the lack of regulations covering aluminum content of parenteral solutions mentioned above and water used to prepare these solutions are shown.
Bookmark/Search this post with
Abstract (Original Language): 
Bu derlemede alüminyum toksisitesinin insan sağlığı ile ilişkisi kalite kontrol açısından değerlendirilmiştir. Alüminyumun insan organizmasına başlıca gi¬riş yollan verilmiş, bu giriş yollarından en önemlisi olan diyaliz ve parenteral solüsyonlarında kullanılan sular, hammaddeler ve konsantre diyaliz solüsyonları için alüminyum sınırlan ve sulardaki kontaminantlan uzaklaştırmak için uygulanan işlemler belirtilmiştir. Hiperfosfatemi ve mide ülseri tedavisinde kullanılan alüminyum jelleri ve antiasitlerin absorpsiyonu ve absorpsiyonu etkileyen bazı faktörler ile ilgili araştır¬malar verilmiştir. Bu araştırmalarda diyalizde olan hastaların alüminyum içeren oral bileşikleri de alma¬ları durumunda daha fazla alüminyum birikimine bağ¬lı serum ve kemik alüminyum düzeyleri ve sonuçlan belirtilerek bu elementin toksisitesinin insan sağlığı ile ilişkisi vurgulanmıştır. Makalenin sonunda öneriler verilmiş ve yukarda belirtilen solüsyonların ve bu solüsyonlarda kullanı¬lan suların alüminyum içeriğine ilişkin yasal düzenle¬melerin eksiklikleri belirtilmiştir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_191.pdf
  • 3-4
164-170
  • Turkish

REFERENCES

References: 

1- Alfrey AC, Le Gendre GR, Kaehny WD. The dialysis encephalopathy syndrome. The New Eng J Med 1976; 294(4):184-188.
2- D'Arcy PF. Aluminium toxicity and the premature infant. Pharm Int 1985; 6 :190-191.
3- Pierides AM, Edwards WG, JR, Cullum ux, et al.
Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980;18:115-124.
4- Parkinson IS, Ward MK, Kerr DNS. Dialysis encephalopathy, bone disease and anemia. J Clin Pathol
1981;34:1285-1294.
5- Prior JC, Cameron EC, Knickerbocker WJ. et al. Dialysis encephalopathy and osteomalacic bone disease.
The Am J Med 1982;72:33-42.
6- Domingo, Jose L. Aluminium in relation to Alzheimer's
disease. Rev toxicol 1993;10(3):121-128.
7- Yokel RA. Aluminium exposure produces learning and memory deficits. A model of Alzheimer's disease. Toxin-Induced Models Neurol Disord. In:Woodruff, Michael L.; Nonneman, Arthur J.Plenum. New York,
1994, pp 301-318.
8- Winship KA. Toxicity of aluminium: A historical review, part 2. Adverse Drug React Toxicol Rev 1993;
12(3): 177-211.
9- Parkinson IS. Fracturing dialysis osteodystrophy and di¬alysis «ncephalopathy. The lancet 1979;24:406-409.
10- Kanis J A. osteomalacia and chronic renal failure. J Clin
Pathol. 1981;34:1295-1307.
11- Smith GD, Winney RJ, Me Lean A, et al. Aluminium related osteomalacia. Kidney Int 1987;32:96-101.
169
12- Ellis HA, Me Carthy JH, and Herrington J. Bone aluminium in hemodialysed patients and m rats injected with aluminium chloride. J Clin Pathol 1979;32:832-844.
13- Gannata JB, Junor BJR, Briggs JD, et al. Effect of acute aluminium overload on calcium and parathyroid-hormo¬ne metabolism. Lancet 1983;501-503.
14-
Şahi
n G and Duru S. Alüminyum toksisitesi. Yeni Tıp
Dergisi 1994;11 (3): 23-32.
15- Is aluminium a dementing ion? Lancet 1992;339:713-
714.
16- Klein GL. Aluminum in parenteral solutions revisited again. Am J Clin Nutr 1995;61:449-56.
17- Klein GL, Alfrey Ac, Shike M. Aluminum and TPN-re-
lated bone disease. Am J Clin Nutr 1992; 55(2):483-4.
18- Driieke TB. Adynamic bone desease, anemia, resistance to erythropoietin and iron-aluminium interaction. Neph-rol Dial Transplant.l993;(suppl.l):12- 16.
19- Iwamoto N, Yamazaki S, Fukuda T, et al. Two cases of parathyroid carcinoma in patients on long-term hemodi-alysis. Nephron 1990;55:429-431.
20- Keshaviah P, Luehmann D. The importance of water tre¬atment in haemodialysis and haemofiltration. Proc ED-TA-ERA 1984;21:111-128.
21- Hodge KC, Day JP, O'Hara M. et al. Critical concentra¬tions of aluminium in water used for dialysis. Lancet
1981:2(8250):802-803.
22- Consensus conference. Diagnosis and treatment of alu¬minium overload in end-stage renal failure patients.
Nephrol Dial Transplant 1993;(Suppl.l):l-4.
23- De Broe ME, D'Haese PC, Couttenye MM, et al. New in¬sights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial
Transplant 1993;(suppl.l):47-50.
24- D'Haese PC, Couttenye MM, De Broe ME. Diognosis and treatment of aluminium bone disease. Nephrol Dial
Transplant 1996;11 (suppl 3):74-79.
25- Klein GL, Coburn JW. Total paranteral nutrition and its effects on bone metabolism. Crit Rev Clin Lab Sci 1994;31(2):135-l-67.
26- Inoe M, Tomioka Jf, Yabushita S, et al. Purification of aqueous albumin solutions with anion exchangers. Jpn
Kokai Tokyo Koho JP 04,17,700 92,187,700 (el. C07 KIS/06), 06 Jul 1992, Appl. 90/315000,19 Nov.1990-
C.A.-117:198496S,1992.
27- Me Elnay JC, D'Arcy PF. Aluminium content of infusi¬on and irrigation fluids. Int J of Pharm 1986;33:261-263.
28- Advisory Notices. WHo Drug Information 1990;4(2):70.
29- Postaire E, Petiot J, Prognon P, et al. Determination de la teneur en aluminum des materiaux plastiques de con-ditionnement pour soluts d'epuration extrarenale. Ann
Pharm Franc 1984;42:113-121.
30- Domingo JL, Gomez M, Sanchez DJ, et al. Effect of va¬rious dietary constituents on gastrointestinal absorption of aluminium from drinking water and diet. Res Com-
mun Chem Pathol Pharmacol 1993;79(3):377-80.
31- Garcia De Jalon CA, Gonzales EM, Zapatero GD, et al. Serum aluminium: Epidemiological features of its toxi-city on hemodialysis patients. Met Ions Biol Med Proc
Int symp 2nd,1992; 238-9.
32- Sewing K.Tolerance of antacids. J Physiol Pharmacol
1993;44 (3 suppl.l):75-7.
33- Nagy E, Jobst K. The kinetics of aluminium-containing antacid absorption m man. Eur J Clin Chem Clin Bioc-
heml994;32(3):119-21.
170

Thank you for copying data from http://www.arastirmax.com